Clinical trials: Stroke Assessment
Ischemic Stroke
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD…
- Trial name
- NCT07371455
- Testing
- LWP779
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
Atrial Fibrillation, Atrial Flutter
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk…
- Trial name
- ARISTOTLE (NCT00412984)
- Testing
- warfarin, apixaban
- Where
- 1,111 sites in United States, Argentina and 39 more
- Volunteers
- 20,976 people
- Sponsor
- Bristol-Myers Squibb
Spasticity, Post-Stroke
A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity.
- Trial name
- NCT03261167
- Testing
- Botulinum toxin A (GSK1358820)
- Where
- 38 sites in Japan
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Stroke, Brain Injuries, Traumatic
The Effects of Lifebloom One on Physical Activity After Acquired Brain Injury
The goal of this clinical trial is to evaluate the effects of Lifebloom One in people who have suffered a stroke or a traumatic brain injury.
- Trial name
- LBO_LCA (NCT05977270)
- Testing
- Lifebloom One
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Lifebloom
Endovascular Thrombectomy, Ischemic Cerebrovascular Accident
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France.
- Trial name
- MATRISS-II (NCT06700824)
- Testing
- OTR4132
- Where
- 15 sites in France
- Volunteers
- 60 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Stroke, Ischemic, Stroke Hemorrhagic
Evaluation of the Effectiveness and Safety of Keeogo™ Dermoskeleton in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Hemiparesis
- Trial name
- NCT03986320
- Testing
- Keeogo™ Dermoskeleton
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- B-Temia, Inc.
Ischemic Stroke
A Study of NCS-01 in Patients With Acute Ischemic Stroke
This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset.
- Trial name
- NCT03915431
- Testing
- NCS-01
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NC Medial Research Inc
Acute Ischemic Stroke
Prospective Evaluation to Characterize the Real-World Performance of the EMBOVAC Aspiration Catheter
A post-market study evaluating the EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
- Trial name
- PERFECT (NCT04531904)
- Testing
- EMBOVAC Aspiration Catheter
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 102 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Heart Failure
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood…
- Trial name
- FINEARTS-HF (NCT04435626)
- Testing
- Finerenone (BAY94-8862)
- Where
- 661 sites in United States, Argentina and 35 more
- Volunteers
- 6,016 people
- Sponsor
- Bayer
Mitochondrial Diseases
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study…
- Trial name
- NCT02473445
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amgen
Stroke
The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers
Double blind, randomized, placebo control, multiple dose, dose escalation study
- Trial name
- NCT02396069
- Testing
- JPI-289
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well
The primary objective of the study is to evaluate the effects of BIIB131 on arterial revascularization (Part 1) and to determine if BIIB131 improves functional outcome as measured by the Modified Rankin Scale (mRS) when compared…
- Trial name
- DAISY (NCT05764122)
- Testing
- BIIB131
- Sponsor
- Biogen
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute coronary syndrome, will yield additional…
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00527943
- Testing
- Vorapaxar
- Volunteers
- 12,944 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Ischemic Stroke
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
- Trial name
- NCT04091945
- Testing
- LT3001 Drug Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 24 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes
This is a phase 2, multicenter, randomized, double-blind (within dose), placebo controlled, parallel-group, dose-range finding study to evaluate the efficacy and safety of TF0023 spray versus placebo in functional improvement of…
- Trial name
- TF0023 (NCT02785120)
- Testing
- TF0023
- Where
- 24 sites in United States
- Volunteers
- 225 people
- Sponsor
- Techfields Inc
Hemodynamic Monitoring
Evaluation of the UltraTrac System as a Non-Invasive Monitor of Hemodynamic Parameters
This study will test the use of the UltraTrac™ system, a small, noninvasive device that uses electrodes on the skin and a small ultrasound sensor to provide measurements of cardiac function in a wide of subjects.
- Trial name
- NCT07862608
- Testing
- Noninvasive Hemodynamic Monitoring System
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- AcQumen Medical, Inc.
Stroke
Evaluation of Transfer Kinematics and Kinetics in Patients Chronic Post-stroke Using the Tibion Bionic Leg
The objective of this clinical study is to examine the acute kinematics and kinetics of utilizing the Tibion Bionic Leg in a sample of chronic post-stroke patients performing sit-to-stand and stand-to-sit transfers across a range…
- Trial name
- NCT01626417
- Testing
- Tibion Bionic Leg
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Tibion Bionics, Inc.
Pseudobulbar Affect (PBA), Stroke
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with…
- Conditions
- Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
- Trial name
- PRISM II (NCT01799941)
- Testing
- Nuedexta (DM 20 mg/Q 10 mg)
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Avanir Pharmaceuticals
Acute Ischemic Stroke, Cerebral Edema
The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the tolerability, safety, and pharmacokinetic characteristics of SIM1910-09 for injection after single/multiple dosing in…
- Trial name
- NCT05200728
- Testing
- SIM1910-09
- Where
- China
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Atrial Fibrillation, Stroke
Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder
This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).
- Trial name
- NCT01920412
- Testing
- LAmbre Left Atrial Appendage(LAA) Occluder
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.